02 Jun 2020
Doherty Seminar Series: Developing medicines for areas of market failure: The need for a “public” pharmaceutical industry
Mark Sullivan, Founder and Managing Director of Medicines Development for Global Health, recently presented a special webinar as part of the Doherty Seminar Series.
Watch the webinar
Mark's presentation, Developing medicines for areas of market failure: The need for a “public” pharmaceutical industry, makes the case for public health mechanisms in pharmaceuticals as well as healthcare to complement the current systems, which includes an understanding of the scope of the data a regulator requires, at the standards they require, without which all product development effort has to be repeated. If successfully implemented, this could add to the treatment armoury for so many of the world’s current conditions and threats through a new path to access.
Mark Sullivan is Founder and Managing Director of Medicines Development for Global Health, the world’s only independent non-profit biopharmaceutical company dedicated to addressing health inequity through developing and delivering new medicines and vaccines for diseases endemic in low and middle income countries. MDGH was the first Australian company (and the first not for profit company in the world) to achieve FDA approval of a new chemical entity: moxidectin, a second generation macrocyclic lactone, was approved for the treatment of onchocerciasis in June 2018 and is now being developed for 4 other neglected tropical diseases. Mark is a clinical research expert and regulatory development project leader.